Discovery

Explore Topics Papers

Docs Terms Privacy

Search Kritoma

Recent searches

Searches you run from this bar will appear here.

GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Knowledge Timeline Gaps (1)Evidence (359)Community (0)

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

SearchSort evidence

All359 Core251 Supporting111 Background0

Active filtersClassification:Core

Showing 205-216 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence.

Yu X; Wang S; Lin K; Guan J

Jan 1, 2026European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

2026PubMedDirectly related

Dual-transporter-targeted oral nanomicelles of semaglutide enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.

Subedi L; Bamjan AD; Kim E; Phuyal S; Sapkota B; Kim KT; Cho SS; Shim JH; Seo JB; Park JW

Jan 1, 2026Journal of controlled release : official journal of the Controlled Release Society

2026PubMedDirectly related

GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

Conforti A; Cifuentes-González C; Agrawal KR; Agrawal R

Jan 1, 2026Drug discovery today

2025CrossrefDirectly related0 citations

Glucagon-Like Peptide-1 Receptor Agonists and Aspiration Risk: A Perioperative Call to Action

Aparna Sinha

Dec 15, 2025Glucagon-Like Peptide-1 Receptor Agonists and Aspiration Risk: A Perioperative Call to Action

2025CrossrefDirectly related21 citations

Efficacy and Safety of <scp>GLP</scp> ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian <scp>NMA</scp>

Binayak Sinha; Samit Ghosal

Nov 1, 2025Obesity

2025Semantic ScholarDirectly related75 citations

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists

Tyson S. Barrett; Juliane O. Hafermann; Shannon Richards; Keith LeJeune; George M. Eid

Sep 17, 2025JAMA Surgery8 influential

2025OpenAlexDirectly related160 citations

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Sean Wharton; Louis J. Aronne; Adam Stefański; Nasreen Alfaris; Andreea Ciudin; Koutaro Yokote; Bruno Halpern; Alpana P. Shukla; Chunmei Zhou; Lisa Macpherson; Sheryl Allen; Nadia N. Ahmad; Suzanne Klise

Sep 16, 2025New England Journal of Medicine

2025OpenAlexDirectly related37 citations

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes

Pareeta Kotecha; Wenxi Huang; Ya-Yun Yeh; Valerie Martino Narvaez; Darlene Adirika; Huilin Tang; Angelina Bernier; Sarah Westen; Steven M. Smith; Jiang Bian; Jingchuan Guo

Sep 15, 2025Archives of Pediatrics and Adolescent Medicine

2025CrossrefDirectly related0 citations

<b>Semaglutide-Associated Severe Gastrointestinal Intolerance and Hepatic Granulomas: A Case Report</b>

Aqsa Khan; Badeeya Rashid; Fareedullah; Sibghatullah

Sep 12, 2025Journal of Diabesity

2025Semantic ScholarDirectly related8 citations

Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.

Andrijana Koceva; A. Janež; M. Jensterle

Sep 1, 2025Best practice & research. Clinical endocrinology & metabolism1 influential

2025Semantic ScholarDirectly related18 citations

Adverse drug reaction patterns of GLP‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database

Tae Hyeon Kim; Kyeongmin Lee; Seoyoung Park; Jiyeon Oh; Jaeyu Park; Hyesu Jo; Hayeon Lee; Jaehyeong Cho; Xuerong Wen; Hanseul Cho; Sunyoung Kim; D. Yon

Apr 2, 2025Diabetes, obesity and metabolism1 influential

2025OpenAlexDirectly related70 citations

The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy

Nadia J Abbass; Raya Nahlawi; Jacqueline K. Shaia; Kevin Allan; David C. Kaelber; Katherine E. Talcott; Rishi P. Singh

Feb 25, 2025American Journal of Ophthalmology

Page 18 of 21Showing 205-216 of total 251 results.

1...171819...21

GLP-1 receptor agonists for obesity treatment — Research Evidence and Topic... | Kritoma

Evidence

GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence.

Dual-transporter-targeted oral nanomicelles of semaglutide enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.

GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

Glucagon-Like Peptide-1 Receptor Agonists and Aspiration Risk: A Perioperative Call to Action

Efficacy and Safety of <scp>GLP</scp> ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian <scp>NMA</scp>

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes

&lt;b&gt;Semaglutide-Associated Severe Gastrointestinal Intolerance and Hepatic Granulomas: A Case Report&lt;/b&gt;

Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.

Adverse drug reaction patterns of GLP‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database

The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy

<b>Semaglutide-Associated Severe Gastrointestinal Intolerance and Hepatic Granulomas: A Case Report</b>